Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients.

Background: Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. gene expression status is associated with tacrolimus dose requirement in renal transplant recipients.